WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel.

Bellerophon Presentation DetailsDate: Wednesday, September 5Time: 9:10am Eastern TimeLocation: The St. Regis New York Hotel, Fontainebleau Foyer, New York, NYWebcast: http://wsw.com/webcast/rrshq28/blph/

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

ContactBellerophon TherapeuticsFabian Tenenbaum, Chief Executive Officer(908) 574-4767

LifeSci AdvisorsBrian Ritchie212-915-2578 britchie@lifesciadvisors.com